|
Cardiomegaly
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity.
|
27099261 |
2017 |
|
Endomyocardial Fibrosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity.
|
27099261 |
2017 |
|
Cardiac Hypertrophy
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
The aim of the present study was to investigate the role of Sirt4 in the pathogenesis of pathological cardiac hypertrophy and the molecular mechanism by which Sirt4 regulates mitochondrial oxidative stress.
|
27099261 |
2017 |
|
Insulin Resistance
|
0.200 |
Biomarker
|
phenotype |
RGD |
These data suggest that SIRT1 and SIRT4 were both involved in the development of insulin resistance and nonalcoholic fatty liver disease.
|
20651844 |
2010 |
|
FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 1
|
0.200 |
Biomarker
|
disease |
RGD |
Calorie restriction on insulin resistance and expression of SIRT1 and SIRT4 in rats.
|
20651844 |
2010 |
|
LIVER DISEASE, ALCOHOLIC, SUSCEPTIBILITY TO, 1
|
0.200 |
Biomarker
|
phenotype |
RGD |
Calorie restriction on insulin resistance and expression of SIRT1 and SIRT4 in rats.
|
20651844 |
2010 |
|
FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 2
|
0.200 |
Biomarker
|
phenotype |
RGD |
Calorie restriction on insulin resistance and expression of SIRT1 and SIRT4 in rats.
|
20651844 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Conclusion: SIRT4 could exert its tumor suppressive function in HCC by inhibiting glutamine metabolism and thereby increasing the adenosine diphosphate (ADP)/AMP levels to phosphorylate AMPKα by LKB1, which blocks the mTOR signaling pathway.
|
30552782 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIRT4 acts as a tumour suppressor of tumour growth by regulating cell metabolism, inflammation, and anti-tumourigenesis.
|
31744516 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, several studies have suggested that SIRT4 may function as either a tumor oncogene or a tumor suppressor gene.
|
30992675 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies demonstrated that SIRT4 can regulate glutamine metabolism and thus act as a tumor suppressor.
|
30745932 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIRT4 has also been identified as a mitochondrial-localized tumor suppressor.
|
30666234 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, our findings show that SIRT4 serves as a tumor suppressor in GC and might act as a novel biomarker and a therapeutic target of GC.
|
30022839 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIRT4 exhibits a tumor suppressor function in human NB and inhibits mitochondrial metabolism and SIRT1 expression in tumor cells, thereby reducing the energy metabolism of tumor cells.
|
30519106 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subsequently, we evaluated the role of SIRT4 with oncogenic or tumor-suppressive activity in cancer, which may provide insight in identifying the underlying mechanism of action of SIRT4 in cancer.
|
29928130 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, several studies have suggested that SIRT4 not only regulates glutamine metabolism, but also serves as a tumor suppressor.
|
28582846 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Low levels of SIRT4 expression was correlated with tumor node metastasis (TNM) stage, histological type of tumor (adenocarcinoma), lymph nodal status, Ki-67 (proliferation index) and poor overall survival.
|
27941873 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A family of orthologues of yeast silent information regulator 3 (SIRT3), 4 (SIRT4) and mitochondrial tumor suppressor 1 (MTUS1) are important mitochondrial tumor suppressor genes which play an important role in the progression of multiple cancers.
|
26785117 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, Sirtuin family of genes shows differential expressions in breast cancer tissues and cells and SIRT1 and SIRT4 seem to play key tumor suppressor roles in breast cancer development.
|
27080717 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies indicate that SIRT4 acts as a tumor suppressor by regulating glutamine metabolism.
|
26986234 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIRT4 has a tumour-suppressive function and may serve as a novel therapeutic target in colorectal cancer.
|
26086877 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, the mitochondrial sirtuin SIRT4 has been reported to function as a tumor suppressor by regulating glutamine metabolism, suggesting that it might have therapeutic potential for treating glutamine-dependent cancers.
|
24368766 |
2014 |
|
Malignant neoplasm of stomach
|
0.040 |
Biomarker
|
disease |
BEFREE |
However, the association of SIRT4 with gastric cancer remains unknown.
|
30745932 |
2019 |
|
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
However, the association of SIRT4 with gastric cancer remains unknown.
|
30745932 |
2019 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We also investigated the effects of SIRT4 overexpression on cell cycle progression and apoptosis of BCPAP cells and studied the role of glutamine metabolism in the effects of SIRT4 on BCPAP cell migration and invasion.
|
30992675 |
2019 |